A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

The indication is based on a phase 3 trial – Empower-Lung 1 – that showed Libtayo given as a monotherapy cut the risk of death by 43% compared to chemotherapy in advanced, PD-L1-high patients ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

These agents illustrate the therapeutic feasibility of an 'immunogenic chemotherapy'; that is, a programme of chemotherapy that aims at stimulating the antitumour immune response as a warranted ...

Becky Kamowitz was appointed executive director of The Skin Cancer Foundation in January 2025. She talks about the ...

The term "chemo curls" is used to describe changes in your hair following chemotherapy treatment for cancer. Chemo often leads to hair loss as one of the side effects, and many people report that ...

Rights Oct 08, 1991 Nov 11, 1991 Sep 30, 1991 Rights ratio: 1 share for every 2 held at a price of Rs 10.0 ...